Ally Bridge Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Ally Bridge Group’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-249,126	Closed	-$665K	–	22
2023 Q1	$665K	Sell	249,126 -619,277	-71%	-$2.4M	0.87%	18
2022 Q4	$3.12M	Hold	868,403	–	–	3.03%	14
2022 Q3	$5.59M	Buy	868,403 +531,913	+158%	+$4.32M	3.69%	11
2022 Q2	$3.24M	Hold	336,490	–	–	2.95%	15
2022 Q1	$4M	Sell	336,490 -17,500	-5%	-$313K	2.97%	15
2021 Q4	$11.5M	Buy	353,990 +10,000	+3%	+$405K	4.03%	9
2021 Q3	$15.4M	Hold	343,990	–	–	5.04%	8
2021 Q2	$18.7M	Buy	343,990 +30,000	+10%	+$1.78M	5.26%	6
2021 Q1	$23.5M	Buy	313,990 +49,740	+19%	+$5.17M	5.69%	5
2020 Q4	$28.7M	Buy	+264,250	New	+$24.1M	7.39%	6

Other funds holding SYRS

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return